PDF
Full
Outline
Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor that occurs in the biliary system, with a hidden onset, poor overall prognosis and high mortality. Futibatinib is a fibroblast growth factor receptor (FGFR) 1-4 inhibitor, which was approved by the U.S. Food and Drug Administration in 2022 for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic ICC with FGFR2 gene fusions or other rearrangements. Phase Ⅰ and Ⅱ clinical trials have shown that futibatinib has good clinical effect on ICC, which can significantly improve the objective response rate and prolong the survival time of ICC patients. The common adverse events include hyperphosphatemia, diarrhea, constipation, and dry mouth, with a high incidence of adverse events.
PDF
79
33
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62199257
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
